| VOL. 27, NO. 3 | May, 2002 |
|---|
|
ABOUT ISGIDAR: |
About the ISGIDAR Website and Discussion Lists (Chief Technology Officer of ISGIDAR) |
ABOUT ISGIDAR NEWSLETTER: |
|---|---|---|
| John R. Glowa, Ph.D. Pfizer Global Res & Devel CNS Discovery Groton Laboratories Eastern Point Rd MS8220-4188 Groton, CT 06340 tel: (860) 686-1835 email: john_glowa@groton.pfizer.com |
Jonathan B. Kamien, Ph.D. BioPsych Consulting 3450 Vista Haven Road Sherman Oaks, CA 91403 email: jkamien@biopsych.com |
Michael A. Nader, Ph.D. Department of Physiology & Pharmacology Wake Forest University School of Medicine Medical Center Blvd. Winston-Salem, NC, 27157 tel: (336) 713-7172 email: mnader@wfubmc.edu |
ISGIDAR e-mail address: ISGIDAR-L@venus.vcu.edu
If you receive this newsletter by regular mail, but are not receiving electronic messages, please sign-up today by filling out this form. In the near future, the newsletter will be sent via e-mail.
INDEX
| 2002 ISGIDAR ANNUAL MEETING: Quebec City |
| NOMINATIONS FOR NEW MEMBERS |
| PRELIMINARY PROGRAM FOR 2002 MEETING |
| POSITIONS AVAILABLE |
The 2002 annual ISGIDAR Scientific Meeting will be held at the Quebec Hilton in Quebec City, Canada immediately preceding the annual scientific meeting of the College on Problems of Drug Dependence. ISGIDAR registration will begin at 8:00AM on Saturday, June 8, 2002. The registration fee is $50. Paper presentations will be scheduled between 9:00AM and 5:00PM and the business meeting will be held from 5:00 to 5:30 PM.
If you wish to advance register ($50 – does not include lunch), please send a check, payable to ISGIDAR, to Dr. Marilyn Carroll, Psychiatry Department, Box 392 UMHC, University of Minnesota, Minneapolis, MN 55455. Receipts for meal costs and registration will be provided at the meeting.
As always, we need to plan ahead a little for lunch at the meeting. We can arrange a reasonable buffet style lunch within our normal limits (e.g., $15), but need to get a head count. If you intend to eat at the meeting, please respond to Jace Glowa ASAP (john_glowa@groton.pfizer.com).
The Department of Behavioral Science and the University of Kentucky have a strong history of research and research training in drug abuse, and seeks to expand its treatment research capacity. A new full-time and tenure track faculty position at the Assistant Professor level is available. The first priority for the successful candidate will be to develop an extramurally funded, nationally-recognized research program focused on the treatment of drug abuse. In addition, the successful candidate will be expected to contribute to the teaching mission of the Department and College. A completed advanced degree (e.g., M.D., Ph.D.) is required, and postdoctoral training is preferred. The Department of Behavioral Science is a multidisciplinary, basic science department within the College of Medicine at the University of Kentucky. The University of Kentucky is a Carnegie Class I research institution moving rapidly toward becoming one of the top 20 public research universities in the United States. The University is located in central Kentucky’s beautiful Bluegrass region, an area known for its high quality of life. Lexington is a growing community of approximately 330,000 with excellent schools, diverse business and industry, excellent recreational opportunities, and a variety of cultural events. Information about the Department is available at www.mc.uky.edu/behavioralscience. Interested applicants should submit a current curriculum vitae, a letter of application outlining their research and teaching experience and interests, and three letters of recommendation to: Thomas H. Kelly, Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, KY 40536-0086, hkelly@uky.edu. Review of applications will begin immediately and will continue until the position is filled. The University of Kentucky is an Affirmative Action/Equal Opportunity Employer.
Postdoctoral positions are available in the Departments of Pharmacology and Psychiatry at the University of Texas Health Science Center at San Antonio. Research in the collaborating laboratories spans human psychopharmacology to behavioral pharmacology in non-humans (monkeys, pigeons, rats and mice) to molecular studies on neurotransmitter transporters. Major areas of research include the following: dependence and abuse liability of benzodiazepines and related GABA modulators; the role of monoamines in opioid dependence and withdrawal; contingency management treatments of cigarette smoking; behavioral and molecular pharmacology of GHB; insulin pathways and reinforcing effects of drugs; and the regulation of dopamine transporters in drug abuse. Successful applicants will conduct research in one or more of the laboratories of the primary investigators (C.P. France, A.Galli, R.J. Lamb and W. Koek). Applicants must have a Ph.D. in pharmacology, physiology, psychology, neuroscience or other related field. Initial appointment is for one year and is renewable for up to three years. Send CV and the names and addresses of three references to: C.P. France, Ph.D., Department of Pharmacology, The University of Texas Health Science Center at San Antonio, Mail Code 7764, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900 (email: france@uthscsa.edu).
We are looking for someone who has demonstrated stable performance in microdialysis and/or self-administration research and who is excited by the challenges of preclinical behavioral pharmacology. Current projects include evaluation of reinforcing strength of opioids and stimulant drugs, characterization of anxiolytic and antipsychotic medications and of cannabinoid and dopaminergic ligands. If interested, please send cover letter and c.v. to: jbergman@hms.harvard.edu or to Jack Bergman / ADARC, McLean Hospital / 115 Mill Street / Belmont MA 02478.
Postdoctoral research fellowships in stimulating, productive program with excellent resources. Prepare as independent investigator.
HUMAN LABORATORY -- behavioral & clinical pharmacology of abused drugs (abuse liability, self-administration, cognitive function, neuroimaging); anti-drug-abuse medications development. Opioids, cocaine, anxiolytics, alcohol, caffeine, nicotine.
CLINICAL TRIALS – testing medications, verbal & behavioral therapies (esp. incentive/motivation-based), and combinations; psychiatric comorbidity research; addiction & pregnancy/women. Opioid, cocaine, tobacco, mixed/other dependencies.
Start Date: Flexible, some now.
Eligibility: citizen, permanent resident. A broad range of backgrounds are appropriate – from clinical/counseling to experimental/neuroscience.
NIH stipend levels: $31-49K+.
Contact Sharon Walsh, George Bigelow, Roland Griffiths, or Maxine Stitzer; BPRU, Behavioral Biology Research Center;. 5510 Nathan Shock Drive; Johns Hopkins Bayview Campus; Baltimore, Maryland 21224-6823. (410) 550-1060; swalsh@jhmi.edu. Cf http://bpru.med.jhu.edu
Post-doctoral positions in the behavioral pharmacology of drug abuse are available in the laboratory of Marilyn E. Carroll, University of MN. Current NIDA-supported projects include studies on the vulnerability to psychostimulant and opiate abuse and behavioral and pharmacological interventions for drug abuse using monkey, rat, and mouse models of phases of the addiction process. Specific areas of focus are sex and hormonal effects, individual differences, genetic knockouts, behavioral economics and interaction of drug abuse with feeding and other natural rewards. Support is from an NIDA-sponsored training grant in NeuroBehavior/NeuroImmune Addiction Research, with faculty and trainees from Psychology, Psychiatry, Pharmacology and Neuroscience. Applicants must have a Ph.D. in one of these areas or a related field. Send a letter, CV and names and contact information of references to: Marilyn E. Carroll, Ph.D., Box 392 Mayo, Minneapolis, MN 55455, Mcarroll@umn.edu, Phone: (612) 626-6289, Fax: (612) 624-8935.
A POSTDOCTORAL POSITION is available for an interested and qualified individual to join a productive research environment investigating the neuropharmacology of cocaine abuse in nonhuman primate models. Models utilized include intravenous drug self-administration and drug discrimination, as well as the use of the noninvasive imaging procedure positron emission tomography (PET). Projects include the investigation of social stress on cocaine self-administration in group-housed macaques, the evaluation of high-affinity dopamine and serotonin transport blockers as potential pharmacotherapies for cocaine abuse, the study of dopamine D2-like antagonists on cocaine’s reinforcing and discriminative stimulus effects and the long-term consequences of cocaine self-administration on dopamine receptor function as determined by PET. Candidate should have a Ph.D. in Pharmacology, Psychology, Neuroscience or related areas. Applicants should send a curriculum vitae, summary of research interests and names of three references to: Michael A. Nader, Ph.D., Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1083; FAX: 336-713-7168; email: mnader@wfubmc.edu